CAMBRIDGE, Mass. & BRISBANE, Australia–(BUSINESS WIRE)–Vaxxas, a clinical-stage biotechnology firm commercializing a novel vaccination platform, in the present day introduced one other key addition to its government management group with the appointment of Doug Cubbin as Chief Monetary Officer. Doug joins Vaxxas as the corporate experiences important progress and advances towards commercialization of its high-density microarray patch (HD-MAP) vaccine supply expertise.
A extremely certified government chief, Doug has greater than 30 years’ expertise in finance, M&A, and enterprise improvement. Most not too long ago, Doug was the Group Chief Monetary Officer at Telix Prescribed drugs Restricted, a world ASX 200 biopharmaceutical firm centered on the event and commercialization of diagnostic and therapeutic merchandise.
Throughout his tenure at Telix, Doug helped develop the market capitalization of the enterprise to AU$2.3 billion (US$1.6 billion) and constructed a world finance group. He was additionally a key member of the group who efficiently accomplished the Telix IPO, and subsequent capital raises, with a complete of AU$270 million (US$180 million) raised. Throughout Doug’s time with Telix, the corporate made 4 acquisitions.
Previous to Telix, Doug held roles of Chief Monetary Officer and Chief Working Officer at ANSTO, Govt Chairman of ANSTO Nuclear Drugs, and Chief Monetary Officer at DHL Oceania and South Pacific.
“It’s been an unbelievable interval of progress for Vaxxas and we’re happy to be strengthening our group with the appointment of Doug Cubbin as Chief Monetary Officer,” Vaxxas Chief Govt Officer David Hoey stated. “Doug’s intensive expertise spans large geographical areas, numerous market sectors, and sophisticated regulatory environments, which brings large worth as we commercialize our vaccination expertise platform.”
Vaxxas Chief Monetary Officer Doug Cubbin added, “The chance Vaxxas has to introduce a novel answer to conventional vaccination strategies is extremely thrilling. I’m thrilled to be becoming a member of the enterprise at this crucial juncture and stay up for seeing the corporate proceed to develop as we work in direction of bringing our first vaccination patch to market.”
Doug’s appointment follows the recruitment to Vaxxas of Scott Fry as Chief Working Officer and Daniel Devine as Chief Enterprise Officer and Basic Counsel, earlier this 12 months. Scott and Daniel joined Vaxxas from Ellume Restricted and Mesoblast Restricted, respectively.
Vaxxas continues to expertise important progress and presently employs over 110 folks. To assist this progress, Vaxxas will transfer right into a state-of-the-art manufacturing facility being constructed by the Queensland Authorities in Brisbane in early 2023.
About Vaxxas’ HD-MAP expertise
The corporate’s proprietary HD-MAP expertise platform makes use of an ultra-high-density array of projections – invisible to the bare human eye – utilized to the pores and skin as a patch sitting inside a small applicator system. When utilized to the pores and skin, the patch delivers vaccine to the plentiful immune cells instantly beneath the pores and skin floor. This strategy has the potential to boost the effectivity and effectiveness of ensuing immune responses of vaccines.
Vaxxas makes use of proprietary dry-coating expertise to use an energetic and steady vaccine onto the projections which gives the potential to eradicate the necessity for vaccine refrigeration throughout storage and transportation – decreasing the useful resource and logistics burden of sustaining the refrigerated “chilly chain”. Ease of use of the HD-MAP might allow simplified administration, doubtlessly encompassing self-administration.
Vaxxas’ HD-MAP is coated with a vaccine candidate and built-in right into a single-use applicator, ready-for-vaccination. All vaccine candidates utilized to the Vaxxas HD-MAP are designed to be efficient and easy-to-use, whereas assembly industrial-scale manufacturing and industrial logistics necessities.
In intensive laboratory testing revealed in PLoS Med, Vaxxas’ HD-MAP delivered vaccines have proven to be steady and stay energetic when saved and transported at room temperature and show potential for a decrease dose when in comparison with needle and syringe supply of vaccine antigens. Vaxxas has accomplished three human medical research with its HD-MAP involving greater than 300 contributors, demonstrating enhanced immune response of vaccine administration by HD-MAP.
About Vaxxas
Vaxxas is a privately held biotechnology firm centered on enhancing the efficiency of present and next-generation vaccines with its proprietary high-density microarray patch (HD-MAP). Vaxxas is concentrating on preliminary purposes in infectious illness and oncology.
A Part I medical research of a COVID-19 vaccine candidate on a patch is presently underway. Vaxxas can be making ready for medical analysis below contract with the US Biomedical Superior Analysis and Improvement Authority (BARDA) on pandemic vaccination options.
Vaxxas’ core expertise was initially developed at The College of Queensland (UQ), and the corporate was established as a start-up in 2011 by UQ’s commercialization firm UniQuest. The corporate was based with the completion of an preliminary fairness financing led by OneVentures Innovation Fund I with co-investors Brandon Capital Companions, Brandon BioCatalyst, and US-based HealthCare Ventures, adopted by an additional financing led by OneVentures. OneVentures Innovation Fund I and Brandon BioCatalyst are supported by the Australian Authorities’s Innovation Funding Fund (IIF) program. The IIF is an Australian Authorities enterprise capital initiative that gives funding capital and managerial experience by way of licensed enterprise capital fund managers to investee firms. Be taught extra at www.one-ventures.com and www.brandoncapital.vc.
Disclaimer
Vaxxas’ HD-MAP delivered vaccines are below investigation and out there just for investigational makes use of. They don’t seem to be out there wherever on the planet on the market or buy. As such, Vaxxas makes no declare that the vaccines are dependable, sturdy, reliable, protected or efficient, and makes no declare that it’s superior to some other vaccine or vaccine supply expertise.
